anticip pain short term updat pt usd
recommend report pure base technic analysi
technic coverag inc last updat septemb
upbeat stock buy rate target usd
success achiev inc shown exponenti rise till
begin decemb stock shown correct due profit
book correct price extend stock
correct a-b-c wave monthli chart therefor downgrad
stock sell rate provid usd immedi target
stock
monthli chart stock price month wma indic
initi bearish stock price macd median line
verg show neg crossov macd setup
indic loss upward momentum rsi indic loss strength
turn level dmi turn dmi
turn indic begin bearish direct price
weekli chart stock price week wma week wma
slope indic trendi downward movement stock price
rsi level slope indic weak
stock price macd median line show neg
crossov indic downsid momentum stock price dmi
slope dmi slope indic downward direct
stock price accord elliot wave theori stock price complet
five impuls wave correct wave wave drag price
till level usd accord calcul correct wave
daili chart stock price wma exactli
support level day wma usd price breach level
target usd easili achiev dmi well dmi
indic direct bearish price rsi level
slope suggest weak stock price macd cross
median line neg crossov indic bearish momentum
stock price
compani name inc tickerpfestock ratingselldowngradeindustri viewoverweightpositivepric week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth inc |decemb
technic project
valuat consensu
bearish stock indic follow fact
stock price month wma
rsi level slope
dmi slope dmi slope
macd verg show neg crossov
format bearish belt hold candl chart
bearish stock indic follow fact
stock price week wma slope
rsi level slope
macd median line show neg crossov
dmi slope dmi slope
bearish stock indic follow fact
stock price day wma
short long crossov evid chart
rsi level
macd cross median line
-dmi dmi
elliot wave project year chart
accord elliot wave theori cycl wave time frame
 year chart five impuls wave eight complet correct cycl
high probabl wave begin price reach level usd
estim
industri rank
recommend
rank industri
support/resist levelspricekey turn cross day move day rsi cross day move day rsi day raw stochast day raw stochast day macd move averag retrac week retrac week cross day move averag cross day move cross day move averag day raw stochast retrac week retrac week cross day move day rsi point level cross day move averag retrac week retrac week cross day move day raw stochast point resist day raw stochast pointprevi day stochast day stochast retrac week highpivot point support day macd oscil stallspivot point support day rsi retrac week retrac week day rsi cross day move inc |decemb
technic project
valuat consensu
incom statement total gross research develop sell gener administr sg oper depreciation- oper profit interest income- incom special interest expense- incom minor incom incom net incom outstand dilut ep dilut ep dividend paid per share actual annual actual quarterli balanc sheet
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom taxes- non-curr minor interest total non-curr total prefer stock common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item
depreciation- defer incom taxes- oper increas decreas increas decreas current assets- decreas increas decreas increas current liabilities- decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant net invest financ activitiesissu issuanc capit stock- repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end inc |decemb
technic project
valuat consensu
revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth inc |decemb
mrqgross mrqoper mrqnet mrqcog mrqsg mrqr sale pfizer inc |decemb
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrqcapex salescap ex salesfre mrqreturn mrqreturn mrqfinanci leverag pfizer inc |decemb
per share item ratio
fiscal per per per per share cash-flow per per valu per book per end stock end stock equiti asset invest capit capit joel greenblatt margin margin margin equiti total debt total pay-out sale account convers rate incom incom margin itemsquarterli item pfizer inc |decemb
outstand equival market properti plant properti plant issuanc prefer issuanc chang pfizer inc |decemb
technic project
valuat consensu
canada complet abus domin investig practic celgen sanofi friday dec dec reuter celgen corp competit bureau complet abus domin investig practic celgen pfizer sanofi competit bureau canada insuffici evid show competit substanti lessened/prev investig celgen pfizer sanofi competit bureau canada bureau unabl conclud competit act contraven astella announc posit top-lin result phase arch trial xtandi thursday dec dec reuter pfizer inc astella pfizer announc posit top-lin result phase arch trial xtandi enzalutamid men metastat hormone-sensit prostat cancer astella pfizer announc posit top-lin result phase arch trial xtandi enzalutamid men metastat hormone-sensit prostat cancer pfizer inc phase arch trial met primari endpoint pfizer inc preliminari safeti analysi arch trial appear consist safeti profil xtandi previou clinic trial pfizer result arch demonstr statist signific improv marker diseas progress radiograph progression-fre surviv kineta enter research collabor licens agreement monday dec dec reuter pfizer inc kineta enter research collabor licens agreement pfizer develop new cancer immunotherapi pfizer inc kineta immuno-oncolog receiv million up-front pfizer inc kio elig receiv million potenti research develop sale mileston payment pfizer inc pfizer fund rig-i target-rel research conduct kineta initi period year pfizer inc kio also elig receiv tier royalti net sale rais dividend pct author new bln share repurchas program friday dec dec reuter pfizer inc declar first-quart dividend author new billion share repurchas program increas quarterli dividend percent per share new program addit billion remain compani current author uk decid refer baxter-hospira deal phase investig thursday dec dec reuter uk competit market author cma decid refer baxter international-hospira uk deal phase investig provis enterpris act abbvi announc humira global patent licens friday nov reuter abbvi inc abbvi announc humira adalimumab global patent licens pfizer pfizer pay royalti abbvi licens humira patent acknowledg valid licens patent abbvi make payment pfizer grant pfizer non-exclus licens specifi date abbvi intellectu properti relat humira inc |decemb
technic project
valuat consensu
consensu view analyst trend stock
stock lower
compar
compar
pfe avgfive-year growth forecast usdgrowth high day day day estim comparisonpfeindustri avg avgprice/earn yield consensu view analyst trend stock
pfizer inc alway deliev
consensu estim
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr inc |decemb
technic project
valuat consensu
stock price show correct top
surg volum top indic distribut price
stock price structur uptrend show bit correct top
date coverag
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
